Protection from concanavalin A (Con A)-induced T cell-dependent hepatic lesions and modulation of cytokine release in mice by sodium fusidate

F. Nicoletti, B. Beltrami, E. Raschi, R. Di Marco, G. Magro, S. Grasso, K. Bendtzen, G. Fiorelli, P. L. Meroni

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

The immunomodulatory effects of the antibiotic sodium fusidate (SF) were tested in a model of T cell-dependent hepatic injury that can be induced in normal mice by a single i.v. injection of Con A. Signs of hepatitis with elevated transaminase activities in plasma, severe infiltration of the liver by neutrophil granulocytes, lymphocytes and monocytes, and necrotic areas were observed in control mice treated intraperitoneally with PBS 24h and 1 h before Con A challenge. T cell- and macrophage-derived cytokines (IL-2, interferon-gamma (IFN-γ), tumour necrosis factor-alpha (TNF-α), IL-1β, IL- 6) were released with different kinetics in the circulation of these mice. SF, 20, 40 or 80 mg/kg, administered 24 h and 1 h before Con A challenge, protected the mice against the hepatitic effects of Con A. The protective effects of SF were dose-dependent and accompanied by profound modifications of blood levels of cytokines induced by Con A, so that, relative to control mice, SF (80 mg/kg)-treated animals showed markedly diminished plasma levels of IL-2, IFN-γ and TNF-α, along with augmented levels of IL-6. These results suggest that SF might be useful in the treatment of immunoinflammatory liver diseases in humans.

Original languageEnglish
Pages (from-to)479-484
Number of pages6
JournalClinical and Experimental Immunology
Volume110
Issue number3
Publication statusPublished - 1997

Fingerprint

Fusidic Acid
Concanavalin A
Cytokines
T-Lymphocytes
Liver
Interferon-gamma
Interleukin-2
Interleukin-6
Tumor Necrosis Factor-alpha
Neutrophil Infiltration
Transaminases
Interleukin-1
Granulocytes
Hepatitis
Liver Diseases
Monocytes
Macrophages
Lymphocytes
Anti-Bacterial Agents
Injections

Keywords

  • Autoimmune diseases
  • Fusidic acid
  • Hepatitis
  • Immunotherapy
  • T cells

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Protection from concanavalin A (Con A)-induced T cell-dependent hepatic lesions and modulation of cytokine release in mice by sodium fusidate. / Nicoletti, F.; Beltrami, B.; Raschi, E.; Di Marco, R.; Magro, G.; Grasso, S.; Bendtzen, K.; Fiorelli, G.; Meroni, P. L.

In: Clinical and Experimental Immunology, Vol. 110, No. 3, 1997, p. 479-484.

Research output: Contribution to journalArticle

Nicoletti, F. ; Beltrami, B. ; Raschi, E. ; Di Marco, R. ; Magro, G. ; Grasso, S. ; Bendtzen, K. ; Fiorelli, G. ; Meroni, P. L. / Protection from concanavalin A (Con A)-induced T cell-dependent hepatic lesions and modulation of cytokine release in mice by sodium fusidate. In: Clinical and Experimental Immunology. 1997 ; Vol. 110, No. 3. pp. 479-484.
@article{450bce115f3743d38fdbeb31e21f1b3e,
title = "Protection from concanavalin A (Con A)-induced T cell-dependent hepatic lesions and modulation of cytokine release in mice by sodium fusidate",
abstract = "The immunomodulatory effects of the antibiotic sodium fusidate (SF) were tested in a model of T cell-dependent hepatic injury that can be induced in normal mice by a single i.v. injection of Con A. Signs of hepatitis with elevated transaminase activities in plasma, severe infiltration of the liver by neutrophil granulocytes, lymphocytes and monocytes, and necrotic areas were observed in control mice treated intraperitoneally with PBS 24h and 1 h before Con A challenge. T cell- and macrophage-derived cytokines (IL-2, interferon-gamma (IFN-γ), tumour necrosis factor-alpha (TNF-α), IL-1β, IL- 6) were released with different kinetics in the circulation of these mice. SF, 20, 40 or 80 mg/kg, administered 24 h and 1 h before Con A challenge, protected the mice against the hepatitic effects of Con A. The protective effects of SF were dose-dependent and accompanied by profound modifications of blood levels of cytokines induced by Con A, so that, relative to control mice, SF (80 mg/kg)-treated animals showed markedly diminished plasma levels of IL-2, IFN-γ and TNF-α, along with augmented levels of IL-6. These results suggest that SF might be useful in the treatment of immunoinflammatory liver diseases in humans.",
keywords = "Autoimmune diseases, Fusidic acid, Hepatitis, Immunotherapy, T cells",
author = "F. Nicoletti and B. Beltrami and E. Raschi and {Di Marco}, R. and G. Magro and S. Grasso and K. Bendtzen and G. Fiorelli and Meroni, {P. L.}",
year = "1997",
language = "English",
volume = "110",
pages = "479--484",
journal = "Clinical and Experimental Immunology",
issn = "0009-9104",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Protection from concanavalin A (Con A)-induced T cell-dependent hepatic lesions and modulation of cytokine release in mice by sodium fusidate

AU - Nicoletti, F.

AU - Beltrami, B.

AU - Raschi, E.

AU - Di Marco, R.

AU - Magro, G.

AU - Grasso, S.

AU - Bendtzen, K.

AU - Fiorelli, G.

AU - Meroni, P. L.

PY - 1997

Y1 - 1997

N2 - The immunomodulatory effects of the antibiotic sodium fusidate (SF) were tested in a model of T cell-dependent hepatic injury that can be induced in normal mice by a single i.v. injection of Con A. Signs of hepatitis with elevated transaminase activities in plasma, severe infiltration of the liver by neutrophil granulocytes, lymphocytes and monocytes, and necrotic areas were observed in control mice treated intraperitoneally with PBS 24h and 1 h before Con A challenge. T cell- and macrophage-derived cytokines (IL-2, interferon-gamma (IFN-γ), tumour necrosis factor-alpha (TNF-α), IL-1β, IL- 6) were released with different kinetics in the circulation of these mice. SF, 20, 40 or 80 mg/kg, administered 24 h and 1 h before Con A challenge, protected the mice against the hepatitic effects of Con A. The protective effects of SF were dose-dependent and accompanied by profound modifications of blood levels of cytokines induced by Con A, so that, relative to control mice, SF (80 mg/kg)-treated animals showed markedly diminished plasma levels of IL-2, IFN-γ and TNF-α, along with augmented levels of IL-6. These results suggest that SF might be useful in the treatment of immunoinflammatory liver diseases in humans.

AB - The immunomodulatory effects of the antibiotic sodium fusidate (SF) were tested in a model of T cell-dependent hepatic injury that can be induced in normal mice by a single i.v. injection of Con A. Signs of hepatitis with elevated transaminase activities in plasma, severe infiltration of the liver by neutrophil granulocytes, lymphocytes and monocytes, and necrotic areas were observed in control mice treated intraperitoneally with PBS 24h and 1 h before Con A challenge. T cell- and macrophage-derived cytokines (IL-2, interferon-gamma (IFN-γ), tumour necrosis factor-alpha (TNF-α), IL-1β, IL- 6) were released with different kinetics in the circulation of these mice. SF, 20, 40 or 80 mg/kg, administered 24 h and 1 h before Con A challenge, protected the mice against the hepatitic effects of Con A. The protective effects of SF were dose-dependent and accompanied by profound modifications of blood levels of cytokines induced by Con A, so that, relative to control mice, SF (80 mg/kg)-treated animals showed markedly diminished plasma levels of IL-2, IFN-γ and TNF-α, along with augmented levels of IL-6. These results suggest that SF might be useful in the treatment of immunoinflammatory liver diseases in humans.

KW - Autoimmune diseases

KW - Fusidic acid

KW - Hepatitis

KW - Immunotherapy

KW - T cells

UR - http://www.scopus.com/inward/record.url?scp=0030732804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030732804&partnerID=8YFLogxK

M3 - Article

VL - 110

SP - 479

EP - 484

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

SN - 0009-9104

IS - 3

ER -